FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

King Faisal Specialist Hospital and Research Centre (KFSH) in Riyadh has successfully introduced a pioneering high-intensity focused ultrasound (HIFU) treatment for prostate cancer for the first time ...

Tool's Danny Carey has revealed a potential timeline for their next studio album and backed that up with talk of some special performances that they would like to put on to coincide with the release.

Diagnostic tools based on artificial intelligence are now making their way into Norwegian hospitals. AI can independently read X-ray images and detect bone fractures, or assess cancer tumors in both ...

Prostate cancer is the most common form of cancer among men in Western countries. The disease is naturally linked to aging. Professor Tone Frost Bathen at NTNU leads a number of research projects on ...

Trident Maritime Systems, a major supplier to the U.S. Navy, has partnered with Gecko Robotics to deploy advanced manufacturing technologies that expand production of the fleet’s essential components.

Please provide your email address to receive an email when new articles are posted on . A new model showed greater accuracy at predicting prostate cancer mortality vs. existing tools. It incorporates ...

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...

Ever since Christopher Ward launched the Bel Canto in late 2022, the brand has become synonymous with bargain-priced haute horological creations, such as the subsequent Bel Canto Classic and C12 Loco.

Researchers have developed a simple new tool that can identify the risk level of metastatic prostate cancer patients earlier. At the time of diagnosis, the test can predict how well the patient will ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.